Anika Therapeutics (ANIK) Operating Income Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Anika Therapeutics | 290.13 Mn | 251.72 Mn | 21.24 Mn | 170.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170.67% |
| Mar 31, 2026 | -28.10% |
| Dec 31, 2025 | 191.63% |
| Sep 30, 2025 | -3,891.36% |
| Jun 30, 2025 | -130.94% |
| Mar 31, 2025 | -71.02% |
| Dec 31, 2024 | -102.85% |
| Sep 30, 2024 | 98.94% |
| Jun 30, 2024 | 50.15% |
| Mar 31, 2024 | 80.04% |
| Dec 31, 2023 | 50.59% |
| Sep 30, 2023 | -32.36% |
| Jun 30, 2023 | -7.39% |
| Mar 31, 2023 | -253.21% |
| Dec 31, 2022 | 279.80% |
| Sep 30, 2022 | -546.00% |
| Jun 30, 2022 | -136.83% |
| Mar 31, 2022 | -382.51% |
| Dec 31, 2021 | 49.18% |
| Sep 30, 2021 | 116.40% |